204 related articles for article (PubMed ID: 38409029)
21. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: A web-based survey.
Tritton T; Bennett B; Brohan E; Grant L; Cooper A; Fladrowski C; Evanochko C; Neary M; Vieira J; Buffa V; Kingswood C
Epilepsy Behav; 2019 Mar; 92():213-220. PubMed ID: 30690322
[TBL] [Abstract][Full Text] [Related]
22. The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex.
Whitney R; Jan S; Zak M; McCoy B
Pediatr Neurol; 2017 Jul; 72():76-80. PubMed ID: 28506505
[TBL] [Abstract][Full Text] [Related]
23. Epilepsy in four genetically determined syndromes of intellectual disability.
Leung HT; Ring H
J Intellect Disabil Res; 2013 Jan; 57(1):3-20. PubMed ID: 22142420
[TBL] [Abstract][Full Text] [Related]
24. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy.
Specchio N; Nabbout R; Aronica E; Auvin S; Benvenuto A; de Palma L; Feucht M; Jansen F; Kotulska K; Sarnat H; Lagae L; Jozwiak S; Curatolo P
Eur J Paediatr Neurol; 2023 Nov; 47():25-34. PubMed ID: 37669572
[TBL] [Abstract][Full Text] [Related]
25. Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries.
Słowińska M; Kotulska K; Szymańska S; Roberds SL; Fladrowski C; Jóźwiak S
Pediatr Neurol; 2021 Feb; 115():21-27. PubMed ID: 33310533
[TBL] [Abstract][Full Text] [Related]
26. 'We've made the best of it. But we do not have a normal life': families' experiences of tuberous sclerosis complex and seizure management.
McDonald A; Goodwin J; Roberts S; Fish L; Vaughan B; Cooper A; Cadwgan J
J Intellect Disabil Res; 2019 Aug; 63(8):947-956. PubMed ID: 30775832
[TBL] [Abstract][Full Text] [Related]
27. International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).
de Vries PJ; Heunis TM; Vanclooster S; Chambers N; Bissell S; Byars AW; Flinn J; Gipson TT; van Eeghen AM; Waltereit R; Capal JK; Cukier S; Davis PE; Smith C; Kingswood JC; Schoeters E; Srivastava S; Takei M; Gardner-Lubbe S; Kumm AJ; Krueger DA; Sahin M; De Waele L; Jansen AC
J Neurodev Disord; 2023 Sep; 15(1):32. PubMed ID: 37710171
[TBL] [Abstract][Full Text] [Related]
28. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review.
Nevitt SJ; Marson AG; Weston J; Tudur Smith C
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD001769. PubMed ID: 30091458
[TBL] [Abstract][Full Text] [Related]
29. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA; Bebin EM; Bhathal H; Jansen FE; Kotulska K; Lawson JA; O'Callaghan FJ; Wong M; Sahebkar F; Checketts D; Knappertz V;
JAMA Neurol; 2021 Mar; 78(3):285-292. PubMed ID: 33346789
[TBL] [Abstract][Full Text] [Related]
30. Epilepsy Management in Tuberous Sclerosis Complex: Existing and Evolving Therapies and Future Considerations.
Nabavi Nouri M; Zak M; Jain P; Whitney R
Pediatr Neurol; 2022 Jan; 126():11-19. PubMed ID: 34740132
[TBL] [Abstract][Full Text] [Related]
31. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
32. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex.
Friedman D; Bogner M; Parker-Menzer K; Devinsky O
Epilepsy Behav; 2013 Apr; 27(1):118-20. PubMed ID: 23399947
[TBL] [Abstract][Full Text] [Related]
33. Translational research: Rett syndrome and tuberous sclerosis complex.
Khwaja OS; Sahin M
Curr Opin Pediatr; 2011 Dec; 23(6):633-9. PubMed ID: 21970827
[TBL] [Abstract][Full Text] [Related]
34. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
Lechuga L; Franz DN
Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
[No Abstract] [Full Text] [Related]
35. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations.
Curatolo P; Jóźwiak S; Nabbout R;
Eur J Paediatr Neurol; 2012 Nov; 16(6):582-6. PubMed ID: 22695035
[TBL] [Abstract][Full Text] [Related]
36. Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis.
de Saint Martin A; Napuri S; Nguyen S
Arch Pediatr; 2022 Dec; 29(5S):5S8-5S13. PubMed ID: 36585069
[TBL] [Abstract][Full Text] [Related]
37. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan.
Mizuguchi M; Ikeda H; Kagitani-Shimono K; Yoshinaga H; Suzuki Y; Aoki M; Endo M; Yonemura M; Kubota M
Brain Dev; 2019 Jan; 41(1):1-10. PubMed ID: 30060984
[TBL] [Abstract][Full Text] [Related]
38. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
Aronica E; Specchio N; Luinenburg MJ; Curatolo P
Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
[TBL] [Abstract][Full Text] [Related]
39. [The Efficacy of Everolimus for Refractory Seizures in Childhood Onset Epilepsy with Tuberous Sclerosis Complex].
Okanishi T; Fujimoto A; Nishimura M; Baba S; Itamura S; Okanari K; Enoki H
Brain Nerve; 2019 Jun; 71(6):611-616. PubMed ID: 31171758
[TBL] [Abstract][Full Text] [Related]
40. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
